There is currently no generic version of Trelegy available. As a result, there is no established generic price for the medication.
When Will Trelegy Go Generic?
The patent protection for Trelegy is set to expire in the coming years. According to DrugPatentWatch.com, the earliest expected patent expiry date for Trelegy is in 2027 [1]. However, the exact date when generic versions can be legally marketed can be influenced by various factors, including patent challenges and regulatory approvals.
What Factors Influence Generic Drug Pricing?
Once a generic version of Trelegy becomes available, its price will be determined by several factors. These typically include the manufacturing costs, the level of competition among generic manufacturers, and the pricing strategies of those companies. The anticipated price of a generic drug is usually significantly lower than the brand-name version due to the reduced research and development costs associated with generic drug production.
How Does Trelegy Work?
Trelegy Ellipta is a once-daily triple-combination inhaler used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) [2]. It contains three active ingredients: fluticasone furoate, umeclidinium, and vilanterol [2]. Fluticasone furoate is an inhaled corticosteroid that reduces inflammation in the airways. Umeclidinium is a long-acting muscarinic antagonist that helps relax the muscles around the airways. Vilanterol is a long-acting beta2-agonist that also helps to open up the airways [2].
What Are the Alternatives to Trelegy?
For patients with asthma and COPD, there are other treatment options available. These include other inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) combinations, long-acting muscarinic antagonists (LAMAs) alone, or other triple therapies, depending on the specific condition and its severity [3]. The choice of treatment is determined by a healthcare professional based on individual patient needs and response to therapy.
---
Sources:
[1] DrugPatentWatch.com. (n.d.). Trelegy patent expiry. Retrieved from https://drugpatentwatch.com/en/product/1045542/trelegy-ellipta
[2] GSK. (2023). TRELEGY® ELLIPTA approved in the US as a once-daily triple therapy for the maintenance treatment of asthma. Retrieved from https://www.gsk.com/en-us/media/press-releases/trelegy-ellipta-approved-in-the-us-as-a-once-daily-triple-therapy-for-the-maintenance-treatment-of-asthma/
[3] U.S. Food and Drug Administration. (2023). FDA drug safety communication. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication